Eli Lilly has a slate of insulin products under development that it hopes will rejuvenate its fortunes. But it also gets 15% of its revenues from existing insulin products, which may come under price pressures as biosimilars hit the market.
Eli Lilly CEO John Lechleiter took a pay cut last year--sort of. His 2012 compensation declined by 15%, to $14.6 million. But as Dow Jones reports, the drop stems from a smaller increase in the value of his pension.
The daring heist of $70 million worth of drugs from an Eli Lilly warehouse two years ago rolled out like the script of a movie. The thieves hit a vulnerable spot on the roof, repelled down ropes, disabled security, then used a loader in the warehouse to fill up a tractor-trailer.
In 2010, burglars waltzed out of an Eli Lilly warehouse with $70 million in drugs. It now appears the thieves had documents that showed them every vulnerability, from where the alarm control room was located to which delivery bay they could safely park their get-away rig in without being seen.
Add up the top-line R&D spending for the top 10 pharma companies in the world and you'd think that nothing had changed from 2011 to 2012. But you'd be very wrong. Big Pharma's heavy hitters in R&D have a wildly mixed record in a fast-changing field. It will be an interesting year ahead. Here's a look at last year's results, and an analysis of where they point. Read the report >>
Novartis has added two more mobile apps to its constellation of digital offerings. This time, cancer patients are the target audience.
Most doctors aren't getting rich off speaking to other physicians about pharma products. But some are, according to a new analysis by ProPublica .
Eisai's Fycompa is a first-of-its-kind seizure drug, a glutamate receptor antagonist and a blockbuster hopeful. The FDA gave the epilepsy drug its approval last year and the Japanese drugmaker is seeking approvals around the world. But Eisai has run into the German pricing agency buzzsaw, and, like its peers, says it is outraged at its treatment.
European pricing policies aren't popular in the drug industry. In fact, little these days is less popular--except, perhaps, patent expirations. Various Big Pharma CEOs have railed at those policies, which seem to change at a moment's notice, but none perhaps as often or as loudly as Eli Lilly CEO John Lechleiter.
With Big Pharma outfits pursuing the same big target, biotech startup Dezima Pharma has landed first-round venture and loan financing totaling $18.6 million to advance a compound in the controversial class of cholesterol drugs known as CETP inhibitors.